Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer

Bayer AG (NASDAQOTH: BAYRY) has entered into a collaborative partnership with Loxo Oncology (NASDAQ: LOXO) that could make it a global leader in cancer drugs that are used in patients based on genetic mutation, rather than the location of cancer. Loxo Oncology's TRK fusion cancer drugs have demonstrated impressive efficacy in a range of cancers, suggesting they could mark an important new direction for cancer treatment. Can this deal pay-off for investors?

Research is showing us that many cancers may be caused by the same genetic mutations and as a result, the same drugs may be able to be used to help improve patient outcomes regardless of whether cancer first took hold in the lung, breast, or somewhere else.

Image source: Getty Images.

Continue reading

Source: Fool.com